FDA Form 3542A is the required document for submitting patent information with a New Drug Application (NDA), amendment, or supplement before FDA approval. Under 21 CFR 314.53, NDA applicants must disclose patents that claim their proposed drug substance, drug product formulation, or method of use. Failure to submit this form correctly can delay your drug approval, result in rejection of your patent listing, or expose your company to legal consequences—including perjury charges under 18 U.S.C. 1001 for willfully false statements.
According to the FDA’s Orange Book, over 3,500 patents are currently listed for approved prescription drugs, and the FTC has challenged more than 200 patents as improperly listed since 2023. Getting Form 3542A right the first time is critical for protecting your intellectual property and avoiding regulatory delays.
📋 What You’ll Learn in This Article:
- 🔍 How to identify which patents must (and must not) be listed on Form 3542A
- ✍️ Step-by-step instructions for completing every field with real-world examples
- ⚠️ Common mistakes that lead to FDA rejection and how to avoid them
- 📊 Key differences between Form 3542A (pre-approval) and Form 3542 (post-approval)
- ❓ Answers to frequently asked questions about patent submission deadlines and disputes
What Is FDA Form 3542A and When Do You Use It?
Form FDA 3542A is the official declaration form for submitting patent information before the FDA approves your NDA, amendment, or supplement. This form differs from Form FDA 3542, which is used after approval. The distinction matters because submitting the wrong form will cause the FDA to reject your patent information.
| Form | Timing | Purpose |
|---|---|---|
| FDA 3542A | Before NDA/supplement approval | Submit patent claims on proposed drugs |
| FDA 3542 | Within 30 days after approval | List patents in the Orange Book |
The Federal Food, Drug, and Cosmetic Act requires NDA applicants to submit patent information for drugs and methods of use described in pending applications. Once approved, these patents appear in the FDA’s “Approved Drug Products with Therapeutic Equivalence Evaluations” publication—commonly called the Orange Book.
Why Patent Listing Matters
Listing patents in the Orange Book provides significant competitive advantages. When a generic manufacturer files an Abbreviated New Drug Application (ANDA) seeking to market a generic version of your drug, they must certify against every listed patent. A “Paragraph IV certification”—where the generic claims your patent is invalid or won’t be infringed—triggers an automatic 30-month stay on FDA approval of the generic. This stay gives brand manufacturers time to litigate patent disputes without facing immediate generic competition.
Which Patents Must Be Submitted?
Not every patent qualifies for Orange Book listing. The FDA accepts only patents that claim:
Patents Eligible for Listing:
- Drug Substance Patents: Patents claiming the active ingredient itself
- Drug Product Patents: Patents claiming the formulation or composition
- Method of Use Patents: Patents claiming approved indications or conditions of use
Patents NOT Eligible for Listing:
- Process patents (manufacturing methods)
- Packaging patents
- Metabolite-only patents
- Intermediate compound patents
- Patents claiming unapproved uses
- Most polymorph patents (with exceptions)
The Polymorph Exception
Polymorph patents—which claim specific crystalline forms of a drug substance—face special requirements. A polymorph patent can be listed if the NDA holder provides certification and test data demonstrating that the patented polymorph performs identically to the drug product in the NDA. Without this evidence, the FDA will not list the patent.
Step-by-Step Instructions for Completing Form 3542A
Form 3542A contains six sections. Each section serves a specific purpose, and incomplete sections will result in FDA rejection. Below is a detailed walkthrough of every field.
Application Information Header
Before entering the numbered sections, complete the header fields identifying your drug product:
Example: Maria works for a pharmaceutical company submitting an NDA for a new diabetes medication. Her NDA number is 12345. She enters “012345” (adding a leading zero to make six digits), lists “Metformin Hydrochloride” as the active ingredient, and identifies the drug as a “Tablet, Extended-Release” dosage form for oral prescription use.
Section 1: General Patent Information
This section captures basic patent details. If your pending NDA has no relevant patents, skip Sections 1-4 and proceed directly to Section 5.
Field 1.a — Patent Number
Enter the U.S. patent number using no more than 10 characters. Submit one patent per form. If you have multiple patents, complete separate Form 3542A submissions for each.
Field 1.b — Patent Issue Date
Enter the date the U.S. Patent and Trademark Office (USPTO) issued the patent. Use MM/DD/YYYY format.
Field 1.c — Patent Expiration Date
Enter the expiration date, including any patent term extension already granted under 35 U.S.C. 156. Do not include pediatric exclusivity—the FDA adds that separately.
Field 1.d — Patent Owner Information
Provide the name, address, phone, fax, and email of each patent owner. Click “Add section 1.d” for additional owners.
Field 1.e — U.S. Agent Information
Complete this field only if the NDA applicant or patent owner does not reside or maintain a business in the United States. Indicate whether the agent represents the patent owner, NDA applicant, or both.
Field 1.f — NDA Applicant Information
Provide complete contact information for the person or entity that submitted the NDA.
Field 1.g — Prior Submission
Indicate whether this patent was previously submitted for this drug product.
Field 1.h — Changes from Prior Submission
If you answered “yes” to 1.g, describe all changes and specify whether each change relates to:
- A patent event (e.g., term extension, PTO decision, court ruling)
- An FDA action (e.g., supplement proposing new conditions of use)
Section 2: Drug Substance (Active Ingredient) Patents
Complete Section 2 if your patent claims the drug substance itself. An important simplification: if your patent qualifies for listing as claiming both the drug substance and drug product, you only need to complete one section—not both.
Scenario: James’s company holds a patent claiming a specific salt form of their active ingredient. The patent does claim the drug substance as described in the NDA, so James answers “yes” to Field 2.1 and skips directly to Field 2.5.
Section 3: Drug Product (Composition/Formulation) Patents
Complete Section 3 if your patent claims the drug product’s formulation or composition. Remember: completing Section 2 or Section 3 is sufficient if your patent qualifies on either basis.
Example: Sarah’s company holds a patent on an extended-release formulation of their drug. The patent claims the specific composition of the tablet matrix—not just the active ingredient. Sarah completes Section 3 because the patent claims the drug product.
Section 4: Method of Use Patents
Complete Section 4 if your patent claims one or more methods of using the proposed drug. Method-of-use patents cover approved indications or conditions of use—not unapproved uses.
Field 4.1 — Does the Patent Claim a Method of Use?
Answer “yes” if the patent includes claims for how the drug is used therapeutically. If yes, you must also complete either Section 2 or Section 3.
Field 4.2 — Identify Patent Claims
For each method of use, list the specific claim numbers from the patent that cover that use. You can group multiple claims for one method (e.g., “claims 1, 2, 3”). For additional methods, click “Add section 4.2.”
Field 4.2a — Labeling Sections
Identify the specific sections and subsections of your proposed product labeling that describe the patented method of use. The format varies by drug type:
Field 4.2b — Use Code Description
Provide a description of the patented method of use. This description becomes the “use code” published in the Orange Book. The FDA has tightened requirements to ensure use codes are not overbroad or ambiguous.
Scenario: Dr. Chen’s company holds a patent claiming a method of treating a specific type of migraine with their drug. The patent’s Claims 4-7 cover this indication. Dr. Chen enters “Claims 4, 5, 6, 7” in Field 4.2, identifies “Section 1, subsection 2” of the labeling in Field 4.2a, and writes a precise description of the migraine treatment method for the use code.
Section 5: No Relevant Patents
Complete Section 5 only if there are no relevant patents for your pending NDA, amendment, or supplement. Leave Sections 1-4 blank when completing Section 5.
This situation occurs when:
- Your patents have expired
- Your patents do not claim the drug substance, drug product, or method of use
- You have no patents on the proposed drug
Section 6: Declaration Certification
Section 6 contains the legal attestation required for all submissions.
Field 6.1 — Declaration Statement
Read the declaration carefully. By signing, you attest that:
- The submission is accurate and complete
- You are familiar with 21 CFR 314.53
- The submission complies with regulatory requirements
Field 6.2 — Signature and Date
Sign and date the form. A willfully false statement is a criminal offense under 18 U.S.C. 1001.
Field 6.3 — Countersignature (If Required)
If the person signing in Field 6.2 does not reside or have a place of business in the United States, an attorney, agent, or authorized official in the U.S. must countersign.
Indicate who is signing:
Where and How to Submit Form 3542A
Submission procedures differ based on timing:
Important: Never submit a copy of the patent itself to the FDA. The FDA only needs the information on the form—not the patent document.
Mark your submission with the appropriate header:
- Pre-approval: “Patent Information”
- Post-approval: “Time Sensitive Patent Information”
Common Mistakes to Avoid
Avoiding these errors will prevent delays and rejection of your patent listing:
What Happens If Your Form Is Incomplete?
The FDA will notify the NDA holder of deficiencies. You then have 15 days to submit an acceptable corrected form. If you miss this window, your original submission date is not preserved—meaning your patent information may be considered untimely.
Do’s and Don’ts for Form 3542A
Do’s ✅
Don’ts ❌
Pros and Cons of Patent Listing in the Orange Book
Pros ✅
Cons ❌
Understanding Patent Term Extension (PTE)
When completing Field 1.c (Patent Expiration Date), include any patent term extension granted under 35 U.S.C. 156. This statute compensates patent owners for time lost during FDA regulatory review.
- Only one patent per approved product can receive PTE
- Application must be filed within 60 days of FDA approval
- The extended patent’s rights are limited to approved uses
Example: A company’s patent was issued in 2020 and would normally expire in 2037. Due to 3 years of regulatory delay, the USPTO granted a 3-year extension. The patent now expires in 2040. Field 1.c should show the 2040 date.
The Orange Book vs. Purple Book: Understanding the Difference
For biological products (biologics), patent information appears in the Purple Book—not the Orange Book.
As of 2024, approximately only 2% of Purple Book entries list any patents—far fewer than the Orange Book. This difference reflects biologics’ unique regulatory framework under the Biologics Price Competition and Innovation Act (BPCIA).
Recent FTC Challenges to Orange Book Listings
Since November 2023, the Federal Trade Commission has challenged over 200 patents as improperly listed in the Orange Book. The FTC targets patents it believes claim device components—like inhaler mechanisms or autoinjectors—rather than drugs themselves.
In Teva v. Amneal (2024), the Federal Circuit affirmed a district court order requiring Teva to delist five patents for its ProAir® HFA inhaler. The court held that patents claiming device components do not “claim the drug” within the meaning of listing requirements.
What this means for NDA holders: Before listing patents, carefully evaluate whether each patent actually claims the drug substance, drug product, or method of use—not merely device components or accessories.
Frequently Asked Questions (FAQs)
Can I submit more than one patent on a single Form 3542A?
No. Each patent requires a separate form submission. The FDA rejects forms containing multiple patents.
What happens if I submit Form 3542A after my NDA is approved?
No, Form 3542A is invalid post-approval. You must use Form 3542 within 30 days of approval for Orange Book listing.
Do I need to submit a copy of the actual patent to the FDA?
No. The FDA does not want patent documents—only the completed form with patent information.
What if my patent issues after NDA approval?
Yes, you can still list it. Submit Form 3542 within 30 days of patent issuance to ensure timely filing status.
Can process patents be listed in the Orange Book?
No. Patents claiming only manufacturing processes are not eligible for listing; only drug substance, drug product, and method-of-use patents qualify.
What happens if the FDA finds my Form 3542A incomplete?
Yes, you receive notification. You then have 15 days to submit a corrected form to preserve your original filing date.
Can a third party challenge my Orange Book patent listing?
Yes. Under 21 CFR 314.53(f)(1), any person may file a “patent listing dispute” with the FDA.
Is the FDA responsible for verifying patent accuracy before listing?
No. The FDA’s role is “ministerial”—it lists patents based on NDA holder submissions without substantive review.
Do generics need to certify against untimely-filed patents?
No. If patent information is filed more than 30 days after issuance, pending ANDAs need not certify against that patent.
Can I withdraw a patent from the Orange Book?
Yes. Send a letter to the appropriate FDA office including the NDA number, affected products, and patent number.
Are there penalties for submitting false patent information?
Yes. Willfully false statements constitute a criminal offense under 18 U.S.C. 1001 and may result in FTC enforcement action.
Do polymorph patents require special documentation?
Yes. You must provide test data proving the polymorph performs identically to the drug product in the NDA.
Where exactly do I submit Form 3542A?
Yes, to the CDER Central Document Room—not the Orange Book staff or Office of Generic Drugs.
Can the FTC challenge my Orange Book patent listing?
Yes. The FTC has challenged hundreds of listings it believes are improper, potentially triggering enforcement action.
Do biologics use Form 3542A for patent listing?
No. Biologics use the Purple Book system with different submission requirements under the BPCIA.